News
Veranova appoints Thomas Rohrer as vice president of bioconjugation: Devens, Massachusetts Wednesday, July 30, 2025, 16:00 ...
Agilent supports India’s global biopharma ambitions with state-of-the-art experience center in Hyderabad: Our Bureau, ...
PCRM survey shows 91% of adults prefer a plant-based diet over injectable drugs for weight loss: Our Bureau, Bengaluru Wednesday, July 30, 2025, 17:45 Hrs [IST] Physicians Committ ...
Alfasigma announces positive results from OLINGUITO phase 3 trial of filgotinib to treat adult patients with active axial spondyloarthritis: Bologna Wednesday, July 30, 2025, 18:0 ...
MAIA Biotechnology receives US FDA fast track designation for ateganosine for the treatment of non-small cell lung cancer: Chicago Wednesday, July 30, 2025, 17:00 Hrs [IST] MAIA B ...
SPPSPTM hosts Orientation Programme 2025 to welcome future pharma professionals: Our Bureau, Mumbai Wednesday, July 30, 2025, 17:30 Hrs [IST] The induction programme 2025 for new ...
Zydus Wellness posts net sales of Rs. 8,577 million in Q1FY26: Our Bureau, Mumbai Wednesday, July 30, 2025, 17:15 Hrs [IST] Reporting its first quarter results for FY 26, Zydus We ...
AI adoption surges in life sciences manufacturing as talent, risk, and quality pressures intensify: Our Bureau, Mumbai Wednesday, July 30, 2025, 16:50 Hrs [IST] Rockwell Automatio ...
US FDA approves PTC Therapeutics’ Sephience to treat children and adults living with phenylketonuria
US FDA approves PTC Therapeutics’ Sephience to treat children and adults living with phenylketonuria: Warren, New Jersey Wednesday, July 30, 2025, 15:00 Hrs [IST] PTC Therapeuti ...
Haleon partners with Indian Dental Association to inaugurate the first D20 International Symposium: Our Bureau, Mumbai Wednesday, July 30, 2025, 15:30 Hrs [IST] Haleon (erstwhile ...
EMA committee recommends approval of BeOne Medicines’ Tevimbra to treat neoadjuvant/adjuvant NSCLC: San Carlos, California Wednesday, July 30, 2025, 12:00 Hrs [IST] BeOne Medici ...
Genethon gets UK MHRA nod to initiate pivotal phase 3 trial of GNT0004, a low-dose microdystrophin gene therapy for Duchenne muscular dystrophy: Paris, France Wednesday, July 30, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results